Drug Profile
IP 1510
Alternative Names: IP-1510; IP-1510DLatest Information Update: 20 Mar 2019
Price :
$50
*
At a glance
- Originator Itis Pharmaceuticals
- Class Peptides
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cachexia; Inflammation
Most Recent Events
- 20 Mar 2019 Discontinued - Phase-II for Cachexia in Australia (SC)
- 20 Mar 2019 Discontinued - Preclinical for Cachexia in Australia (PO)
- 20 Mar 2019 Discontinued - Preclinical for Inflammation in Australia (PO)